Lb Pharmaceuticals (LBRX) Cash from Investing Activities (2024 - 2026)

Lb Pharmaceuticals' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$32000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 100.64% year-over-year to -$32000.0; the TTM figure through Mar 2026 stood at $18.4 million (changed N/A YoY), while the FY2025 annual figure was -$39.9 million, down 271.68% from the prior year.
• Cash from Investing Activities was -$32000.0 for Q1 2026 at Lb Pharmaceuticals, up from -$40000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $13.5 million in Q4 2024 to a low of -$40000.0 in Q4 2025.
• Historically, Cash from Investing Activities has averaged $4.6 million across 3 years, with a median of $2.5 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities plunged 100.3% in 2025, then slumped 100.64% in 2026.
• A 3-year view of Cash from Investing Activities shows it stood at $13.5 million in 2024, then plunged by 100.3% to -$40000.0 in 2025, then gained by 20.0% to -$32000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$32000.0 (Q1 2026), -$40000.0 (Q4 2025), and $5.0 million (Q1 2025), per Business Quant data.